AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID
Breakpoints
The Cost-Effectiveness of Beta Lactamase Inhibitors
It would be our first vli to inhibit metallobatal actumases which is quite important it is being developed currently or considered as a standalone beta lactumase inhibitor. It has a long half-life so that's good because it would facilitate use with different dosing strategies and multiple beta lactams in order to optimize that beta lactamase inhibitor exposure all right. Our next late-breaker study came to us from our friends up in western Canada and this was one of those studies that I think we all kind of know what the results are going to be but it's really nice to have an unwriting to take to like your c-suite if this is a problem
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode